Xeris Biopharma Holdings Inc Quick Ratio (XERS) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Xeris Biopharma Holdings Inc   (NASDAQ: XERS)

Xeris Biopharma Holdings Inc 's Quick Ratio

XERS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Xeris Biopharma Holdings Inc 's Cash & cash equivalent grew by 117.89 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Xeris Biopharma Holdings Inc 's Quick Ratio to 2.16, Quick Ratio remained below Xeris Biopharma Holdings Inc average.

Within Major Pharmaceutical Preparations industry 283 other companies have achieved higher Quick Ratio than Xeris Biopharma Holdings Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 2056, from total ranking in the first quarter 2026 at 2440.

Explain Quick Ratio?
How much Cash & cash equivalents XERS´s has?
What are XERS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XERS Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 18.55 % 24.74 % 9.09 % 27.67 % 26.07 %
Y / Y Cash & cash equivalent Change 310.72 % 91.22 % 55.04 % 31.98 % -23.57 %
Quick Ratio MRQ 2.16 0.94 1.01 0.79 0.62
XERS's Total Ranking # 2056 # 2440 # 2538 # 2876 # 2894
Seq. Current Liabilities Change -4.86 % 8.23 % -5.7 % 22.1 % 0.1 %
Seq. Cash & cash equivalent Change 117.89 % 0.64 % 21.23 % 54.5 % 1.45 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 284
Healthcare Sector # 488
Overall Market # 1351


Quick Ratio Statistics
High Average Low
17.91 4.51 0.61
(Dec 31 2017)   (Mar 31 2025)




Financial Statements
Xeris Biopharma Holdings Inc 's Current Liabilities $ 113 Millions Visit XERS's Balance sheet
Xeris Biopharma Holdings Inc 's Cash & cash equivalent $ 243 Millions Visit XERS's Balance sheet
Source of XERS's Sales Visit XERS's Sales by Geography


Cumulative Xeris Biopharma Holdings Inc 's Quick Ratio

XERS's Quick Ratio for the trailling 12 Months

XERS Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 19.78 % 21.41 % 22.35 % 21.54 % 15.39 %
Y / Y Cash & cash equivalent TTM Growth 115.61 % 34.89 % 4.71 % -8.42 % -14.7 %
Quick Ratio TTM 1.22 0.85 0.77 0.69 0.68
Total Ranking TTM # 1447 # 1813 # 1440 # 1514 # 1498
Seq. Current Liabilities TTM Growth 4.02 % 5.65 % 2.24 % 6.6 % 5.44 %
Seq. Cash & cash equivalent TTM Growth 49.3 % 16.64 % 14.03 % 8.58 % -6.6 %

Quick ratio ranking by company, industry and sector >> Back to XERS Financial Strength Comparisons >> Go to Compare XERS Quick Ratio to its Competitors

On the trailing twelve months basis XERS Cash & cash equivalent more than doubled by 310.72 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Xeris Biopharma Holdings Inc 's Quick Ratio to 1.22, Quick Ratio remained below XERS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 435 other companies have achieved higher Quick Ratio than Xeris Biopharma Holdings Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3875.

Explain Quick Ratio?
How much Cash & cash equivalents XERS´s has?
What are XERS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 436
Healthcare Sector # 892
Within the Market # 2056


trailing twelve months Quick Ratio Statistics
High Average Low
12.83 1.89 0.61
(Mar 31 2019)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions
Silence Therapeutics Plc  5.67 $ 72.100  Millions$ 12.714  Millions
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Mereo Biopharma Group Plc  5.37 $ 30.506  Millions$ 5.677  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions
Immuneering Corporation  5.14 $ 41.731  Millions$ 8.116  Millions
Lyell Immunopharma Inc   5.12 $ 204.102  Millions$ 39.867  Millions
Altimmune inc   5.04 $ 63.008  Millions$ 12.501  Millions
Rani Therapeutics Holdings Inc   5.02 $ 53.391  Millions$ 10.638  Millions
Phio Pharmaceuticals Corp  4.99 $ 12.996  Millions$ 2.606  Millions
Immunic Inc   4.96 $ 155.098  Millions$ 31.260  Millions
Silo Pharma Inc  4.90 $ 5.227  Millions$ 1.066  Millions
Atossa Therapeutics Inc   4.81 $ 26.204  Millions$ 5.451  Millions
Calcimedica Inc   4.71 $ 18.600  Millions$ 3.950  Millions
Kala Bio inc   4.70 $ 7.229  Millions$ 1.538  Millions
Septerna Inc   4.69 $ 372.322  Millions$ 79.316  Millions
Viking Therapeutics Inc   4.57 $ 501.663  Millions$ 109.656  Millions
Camp4 Therapeutics Corporation  4.51 $ 86.398  Millions$ 19.142  Millions

Date modified: 2026-09-26T07:40:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.